Search
Menu
Home
HTB
2020
March
12
HTB
12 March 2020
Contents
Editorial
HTB 12 March 2020 now online
HTB survey 2020 – please help with feedback
Special reports
Fit for purpose: antiretroviral treatment optimisation March 2020
HIV pipeline 2020: new drugs in development – March 2020
Conference reports
Conference on Retroviruses and Opportunistic Infections (CROI 2020)
CROI 2020: Special session on COVID-19
Monthly islatravir for PEP and PrEP: 12 pills a year could cover unmet need for HIV prevention in billions of people globally
Long-acting cabotegravir and rilpivirine injections support two-monthly dosing
Safety and PK of bNAb elipovimab (GS-9722) support two-weekly dosing
First results with long-acting capsid inhibitor GS-6207: oral and subcutaneous formulations for use in naïve and multidrug resistance
Predicted diabetes risk with first-line ART regimens: results from the ADVANCE trial
Postpartum weight gain is higher with dolutegravir- compared with efavirenz-based ART among African women
London patient is second person to be cured of HIV from allogeneic stem-cell transplant
The London Patient tells his story as second person cured of HIV
Treatment access
Dolutegravir/lamivudine FDC recommended by NHS England
PDFs
12 March 2020 vol 21 no 3
HTB RSS
Current issues
March 2024
February 2024
January 2024
Back issues
Special report
Modelling study challenges links between gender and PrEP: event-based dosing and easier daily dosing should work for all
12 February 2024
More from HTB
Conference reports
Conference shortcuts
Articles by subject
PDFs
Subscribe
HTB homepage
Home
i-Base homepage